EUVIMEDEUVIMED entdecken
Crossref

Incidence and clinical impact of bile ducts changes after multibipolar radiofrequency ablation for hepatocellular carcinoma

Eloi Varin, Paul Beunon, Gisèle N'Kontchou, Arthur Petit, Lorenzo-Carlo Pescatori, Nathalie Ganne-Carrié, Jean-Charles Nault, Olivier Seror, Olivier Sutter

European Radiology · 2024

DOI: 10.1007/s00330-024-10617-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Radiology, 2024. Verfasst von Eloi Varin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Radiology Unit, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique Hôpitaux de Paris, Bobigny, Fra…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Radiofrequency Ablation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to evaluate the incidence and clinical implications of bile duct changes following multibipolar radiofrequency ablation (mbpRFA) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Radiological, clinical, and biological data from consecutive cirrhotic patients who underwent first-line mbpRFA between 2007 and 2014 for uninodular HCC ≤ 5 cm were retrospectively collected. Follow-up imaging was reviewed to identify bile duct changes and factors associated with biliary changes were assessed using multivariable analysis. Baseline and 6-month liver function tests were compared in patients with and without bile duct changes. Complications, cirrhosis decompensation, and survival rates were compared in both groups. RESULTS: A total of 231 patients (mean age 68 years [39-85], 187 men) underwent 266 mbpRFA sessions for uninodular HCC (mean size 26 mm). Of these, 76 (33%) developed bile duct changes (upstream bile duct dilatations and/or bilomas) with a mean onset time of 3 months. Identified risk factors for these changes were the infiltrative aspect of the tumor (p = 0.035) and its location in segment VIII (p < 0.01). The average increase in bilirubin at 6 months was higher in the group with biliary changes (+2.9 vs. +0.4 µg/mL; p = 0.03). There were no significant differences in terms of complications, cirrhosis decompensation at 1 year (p = 0.95), local and distant tumor progression (p = 0.91 and 0.14 respectively), and overall survival (p = 0.4) between the two groups. CONCLUSION: Bile duct changes are common after mbpRFA for HCC, especially in tumors with an infiltrative aspect or those located in segment VIII. These changes do not appear to negatively impact the course of cirrhosis at 1 year or overall survival. CLINICAL RELEVANCE STATEMENT: Bile duct changes following mbpRFA for HCC are relatively common. Nevertheless, they do not raise clinical concerns in terms of complications, deterioration in liver function, or survival rates. Consequently, specific monitoring or interventions for these bile duct changes are not warranted. KEY POINTS: • Bile duct changes are frequently observed after multibipolar radiofrequency ablation for hepatocellular carcinoma, occurring in 33% of cases in our study. • Patients with bile duct changes exhibited a higher increase in bilirubin levels at 6 months but no more cirrhosis decompensation or liver abscesses. • Biliary changes following multibipolar radiofrequency ablation for hepatocellular carcinoma are not alarming and do not necessitate any specific monitoring or intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsRadiofrequency AblationHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAged, 80 and overAdultBile DuctsIncidenceRisk FactorsTreatment OutcomeLiver CirrhosisPostoperative Complications

Stichwörter der Autor:innen

Ablation techniquesHepatocellular carcinomaIntrahepatic bile ductsLiver cirrhosisRadiofrequency ablation

Autor:innen und Institutionen

  • Interventional Radiology Unit, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique Hôpitaux de Paris, Bobigny, France.
  • Liver Unit, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique Hôpitaux de Paris, Bobigny, France.
  • Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Sorbonne Paris Nord, Bobigny, France.
  • Centre de recherche des Cordeliers, Sorbonne Université, Inserm, Université Paris Cité, team « Functional Genomics of Solid Tumors », Equipe labellisée Ligue Nationale Contre le Cancer, Labex OncoImmunology, F-75006, Pa…
  • Interventional Radiology Unit, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique Hôpitaux de Paris, Bobigny, France. olivier.sutter@aphp.fr.

Zitieren

APA

Varin, E., Beunon, P., N'Kontchou, G., Petit, A., Pescatori, L. C., Ganne-Carrié, N., Nault, J. C., Seror, O., & Sutter, O. (2024). Incidence and clinical impact of bile ducts changes after multibipolar radiofrequency ablation for hepatocellular carcinoma. European Radiology. https://doi.org/10.1007/s00330-024-10617-7

Vancouver

Varin E, Beunon P, N'Kontchou G, Petit A, Pescatori LC, Ganne-Carrié N, et al. Incidence and clinical impact of bile ducts changes after multibipolar radiofrequency ablation for hepatocellular carcinoma. European Radiology. 2024. doi:10.1007/s00330-024-10617-7

BibTeX
@article{Varin2024,
  author = {Varin, Eloi and Beunon, Paul and N'Kontchou, Gisèle and Petit, Arthur and Pescatori, Lorenzo-Carlo and Ganne-Carrié, Nathalie and Nault, Jean-Charles and Seror, Olivier and Sutter, Olivier},
  title = {Incidence and clinical impact of bile ducts changes after multibipolar radiofrequency ablation for hepatocellular carcinoma},
  journal = {European Radiology},
  year = {2024},
  doi = {10.1007/s00330-024-10617-7}
}
Kostenlos starten →